Impact of adjuvant endocrine therapy utilization in male patients with early breast cancer: results from a large German real-world claims data analysis
A significant proportion of male patients with early BC does not use ET. However, the use of ET plays a key role in improving survival outcomes for male patients with early BC. Efforts to improve the use of ET, including patient education and management of side effects, are essential to optimize treatment outcomes.
Authors
- Alexandra von Au (ORCID: https://orcid.org/0000-0001-7649-4914)
- Dominik Dannehl (ORCID: https://orcid.org/0000-0002-7653-8283)
- Léa Louise Volmer
- Andreas Hartkopf
- Markus Wallwiener (ORCID: https://orcid.org/0000-0002-4139-9340)
- D. Wallwiener (ORCID: https://orcid.org/0000-0002-4635-5283)
- Sara Yvonne Brucker (ORCID: https://orcid.org/0000-0001-8588-1094)
- Anna Sophie Scholz (ORCID: https://orcid.org/0000-0002-3439-3872)
- Stephanie Wallwiener (ORCID: https://orcid.org/0000-0003-2045-650X)
- Tobias Engler (ORCID: https://orcid.org/0000-0002-8063-2053)
- Tjeerd M. H. Dijkstra (ORCID: https://orcid.org/0000-0002-4450-701X)
- Armin Bauer (ORCID: https://orcid.org/0000-0002-2171-1333)
- Sabine Hawighorst‐Knapstein
- Ariane Chaudhuri
- Markus Hahn
Institutions
- Heidelberg University (DE)
- AOK (DE)
- STZ eyetrial (DE)
- University Hospital in Halle (DE)
- University Hospital Cologne (DE)
- University of Tübingen (DE)
Publication Details
- Journal
- Archives of Gynecology and Obstetrics
- Published
- 2025-10-17
- DOI
- https://doi.org/10.1007/s00404-025-08198-x
- Primary Topic
- Male Breast Health Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00